Abstract
Persons living with HIV (PLWH) are at increased risk of tuberculosis (TB). HIV-associated TB is often the result of recent infection with Mycobacterium tuberculosis (Mtb) followed by rapid progression to disease. Alveolar macrophages (AM) are the first cells of the innate immune system that engage Mtb, but how HIV and antiretroviral therapy (ART) impact on the anti-mycobacterial response of AM is not known. To investigate the impact of HIV and ART on the transcriptomic and epigenetic response of AM to Mtb, we obtained AM by bronchoalveolar lavage from 20 PLWH receiving ART, 16 control subjects who were HIV-free (HC), and 14 subjects who received ART as pre-exposure prophylaxis (PrEP) to prevent HIV infection.
Following in-vitro challenge with Mtb, AM from each group displayed overlapping but distinct profiles of significantly up- and down-regulated genes in response to Mtb. Compared to HC subjects, AM isolated from PLWH and PrEP subjects presented a substantially weaker transcriptional response. Further investigation of chromatin structure revealed that AM from control subjects challenged with Mtb responded with pronounced accessibility changes in over ten thousand regions. In stark contrast, AM obtained from PLWH and PrEP subjects displayed no significant changes in their chromatin state in response to Mtb. Collectively, these results revealed a previously unknown adverse effect of ART on the epigenetic landscape and transcriptional responsiveness of AM.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
This work was supported by grant 1R01AI124349 from the National Institutes of Health, USA, to ES and LBB; and in part by the Fonds de la Recherche Quebec-Sante (FRQ-S) Reseau SIDA/Maladies infectieuses and Therapie cellulaire (JPR). JS is supported through grants PID2019-106859GA-I00 and RYC-2017-23560 from the Spanish Ministry of Science and Innovation (MICINN). This research was supported through a resource allocation in the Cedar high performance computing cluster by Compute Canada and WestGrid.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
The study was approved by the Research Ethics Board of the McGill University Health Center (MUHC) (MP-CUSM-15-406). Participants were recruited at the McGill University Health Centre (MUHC, Montreal, Canada).
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Data Availability
All data associated with this study are present in the main text or the Supplementary Materials. RNA, ATAC and ChIP-seq raw sequences and corresponding quantification matrices analysed is this work were submitted to NCBI's Gene Expression Omnibus repository (data is being processed, accession number will be available for publication).
